# Development of a multi-year pediatric antibiogram in Georgia identifies antibiotic resistance changes over the past ten years

**Authors:** Matthew Linam, Madeleine Goldstein, Tracy Huang, Adrianna Westbrook, Robert C. Jerris, Mark D. Gonzalez

PMC · DOI: 10.1017/ash.2025.32 · Antimicrobial Stewardship & Healthcare Epidemiology : ASHE · 2025-02-12

## TL;DR

This study tracks antibiotic resistance trends in Georgia's children's hospitals over ten years, showing some resistance patterns have improved while others remain stable.

## Contribution

The paper provides a multi-year pediatric antibiogram for Georgia, revealing longitudinal changes in antibiotic resistance patterns.

## Key findings

- MRSA rates decreased from 49% in 2014 to 33.5% in 2023.
- S. pneumoniae susceptibility to amoxicillin/clavulanate and clindamycin increased significantly.
- Gram-negative bacteria showed stable to slightly decreased susceptibility to common antibiotics.

## Abstract

Antibiograms monitor antibiotic resistance trends and help guide empiric antibiotic treatment. A statewide pediatric antibiogram can help inform stewardship efforts.

Annual pediatric antibiograms for the five children’s hospitals in Georgia from 2014–2023 were collected. All sites used the Clinical and Laboratory Standards Institute guidelines for antibiogram development. Antibiogram data were combined, and the most common bacteria were included: Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae complex and Pseudomonas aeruginosa. Interhospital differences were compared for methicillin-susceptible S. aureus (MSSA), methicillin-resistant S. aureus (MRSA), E. coli and K. pneumoniae. The combined data from 2014 and 2023 were compared to demonstrate antibiotic susceptibility changes over time.

Data in 2023 for MSSA and MRSA showed clindamycin susceptibility was 78% and 82%, respectively. S. pneumoniae susceptibility to amoxicillin/clavulanate was 96%. E. faecalis resistance to ampicillin and vancomycin was rare. For all included gram-negative bacteria, susceptibility remained high to 3rd generation cephalosporins (90%–92%) and meropenem (95%–99%). From 2014 to 2023, the rate of MRSA decreased from 49% to 33.5%. S. pneumoniae susceptibility to amoxicillin/clavulanate and clindamycin significantly increased. For E. coli, there was a significant decrease in susceptibility for cefazolin (90% to 84%), ceftriaxone (95% to 92%), and meropenem (100% to 99%). There were nonsignificant decreases in susceptibility for K. pneumoniae.

Over the past 10 years, MRSA rates decreased, S. pneumoniae antibiotic susceptibility increased, and gram-negative bacilli susceptibility was stable to slightly decreased. Georgia antibiogram data support the recommended antibiotic treatment for common pediatric infections.

## Linked entities

- **Chemicals:** clindamycin (PubChem CID 446598), amoxicillin/clavulanate (PubChem CID 6435924), ampicillin (PubChem CID 6249), vancomycin (PubChem CID 14969), cefazolin (PubChem CID 33255), ceftriaxone (PubChem CID 5479530), meropenem (PubChem CID 441130)
- **Species:** Staphylococcus aureus (taxon 1280), Streptococcus pneumoniae (taxon 1313), Enterococcus faecalis (taxon 1351), Escherichia coli (taxon 562), Klebsiella pneumoniae (taxon 573), Enterobacter cloacae complex (taxon 354276), Pseudomonas aeruginosa (taxon 287)

## Full-text entities

- **Diseases:** infections (MESH:D007239)
- **Chemicals:** cephalosporins (MESH:D002511), ceftriaxone (MESH:D002443), vancomycin (MESH:D014640), ampicillin (MESH:D000667), clindamycin (MESH:D002981), amoxicillin/clavulanate (MESH:D019980), meropenem (MESH:D000077731), cefazolin (MESH:D002437), methicillin (MESH:D008712)
- **Species:** Enterobacter cloacae (species) [taxon 550], Staphylococcus aureus (species) [taxon 1280], Klebsiella pneumoniae (species) [taxon 573], Escherichia coli (E. coli, species) [taxon 562], Streptococcus pneumoniae (species) [taxon 1313], Pseudomonas aeruginosa (species) [taxon 287], Enterococcus faecalis (species) [taxon 1351]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11822576/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11822576/full.md

## References

28 references — full list in the complete paper: https://tomesphere.com/paper/PMC11822576/full.md

---
Source: https://tomesphere.com/paper/PMC11822576